Giant Axonal Neuropathy

Total Page:16

File Type:pdf, Size:1020Kb

Giant Axonal Neuropathy Proc. Nati. Acad. Sci. USA Vol. 82, pp. 920-924, February 1985 Neurobiology Giant axonal neuropathy: Acceleration of neurofilament transport in optic axons (axonal morphometry/fluorography/2,5-hexanedione/intermediate filaments/i proteins) SALVATORE MONACO, LUCILA AUTILIO-GAMBETTI, DAVID ZABEL, AND PIERLUIGI GAMBETTI* Division of Neuropathology, Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106 Communicated by George B. Koelle, September 4, 1984 ABSTRACT Giant axonal neuropathies are a group of ac- ane are widely used as solvents and have caused outbreaks quired and inherited human diseases morphologically charac- of polyneuropathies among industrial workers (11, 12) and in terized by accumulation of neurofilaments (NF) in enlarge- individuals intentionally inhaling glue vapors (13). The distal ments of preterminal regions of central and peripheral axons. giant axonopathy produced by these compounds in experi- Slow axonal transport was studied in the optic systems of rats mental and clinical conditions is indistinguishable from that treated with 2,5-hexanedione, a toxic compound that produces of the inherited forms (4). an experimental model of giant axonal neuropathy. The trans- The pathogenetic mechanism of distal axonal accumula- port rate of NF and of two other polypeptides ofMr 64,000 and tion of NF is unknown. Two main hypotheses have been put 62,000 were selectively increased. Other components of the forward, both assuming that NF are transported at decreas- slow axonal transport were not affected. Acceleration of la- ing rates and are eventually blocked (14, 15). However, slow beled NF was also observed when 2,5-hexanedione was given axonal transport has not been studied. after [35S~methionine administration. Morphometric analysis We analyzed the labeled polypeptides migrating along the revealed that the number of NF and the axon size were de- optic system with the slow component of the axonal trans- creased in regions of optic axons proximal to the enlargements. port in rats treated with 2,5-HxD and in controls. The find- It is suggested that acceleration of NF transport leads to a lon- ings were correlated with morphometric analyses of axons gitudinal redistribution of NF: NF decrease proximally and in- and axonal cytoskeleton. This study has been reported in crease distally, forming NF-containing enlargements. Evi- part (16, 17). dence was obtained that polypeptides of Mr 64,000 and 62,000 are cytoskeletal components related to intermediate filaments, MATERIALS AND METHODS normally migrating with the component a of the slow axonal Induction of the Neuropathy. Male Sprague-Dawley rats transport. The 2,5-hexanedione axon may provide insight into (12 weeks old) were continuously given 0.5% 2,5-HxD in the pathogenesis of inherited and acquired giant axonal neuro- drinking water for up to 14 weeks. Age-matched controls re- pathies and offers a model to investigate the relationship be- ceived regular drinking water or similar amounts of the non- tween number of NF and axonal size in central axons. neurotoxic compound 2,4-hexanedione (18). Morphological Studies. Experimental and control rats were Axonal transport involves the migration of highly ordered sacrificed at weekly intervals from the 3rd to 14th week of complexes of proteins at five distinct rates (1). In mammali- treatment. Rats were perfused through the ascending aorta an optic axons two groups of proteins, slow component a with 0.2 M sodium cacodylate buffer, pH 7.4, followed by (SCa) and slow component b (SCb), have transport rates of 5% (wt/vol) glutaraldehyde in 0.1 M sodium cacodylate buff- 0.3 mm/day and 2-3 mm/day, respectively (2). SCa com- er, pH 7.4, with 0.03% CaCl2, at 37°C. Samples were taken prises neurofilaments (NF), tubulin, and microtubule-associ- at 5-mm intervals from the sciatic, sural, tibial, and plantar ated proteins, whereas SCb carries over 200 polypeptides, nerves. The primary optic pathway was sampled at 2-mm including actin, calmodulin, neuronal-specific enolase, and intervals. Tissues were postfixed with 2% osmium tetroxide, creatine kinase (3). dehydrated in graded acetone, and embedded in Spurr resin. The use of experimental models has added new insight to Morphometric analysis of axons and quantitation of microtu- the role that disturbances of the axonal transport play in the bules (MT) and NF were performed in three rats after 11 pathophysiology of human diseases of the central and pe- weeks of intoxication and in three controls. From each rat, ripheral nervous systems. 12 random micrographs of entire cross-sections of one optic Giant axonal neuropathies are a group of diseases com- nerve, 5 mm from the eyeball, were taken at x2700 and prising toxic as well as inherited conditions (4, 5). The patho- printed at x 10,000 final magnification. The area of each logical hallmark of these diseases is the presence of masses axon was determined by using a computer-assisted digitizer. of NF producing focal enlargements in the preterminal re- Axons with the major diameter twice the size of the minor gions of axons. In advanced stages of the neuropathy, the one were discarded. Totals of 6679 and 10,182 axons were enlargements extend proximally and the distal part of the in- measured in control and experimental animals, respectively. volved axons eventually undergoes degeneration in several To determine number of MT and NF per axon, optic nerves central and peripheral axonal pathways. However, in experi- were photographed randomly at x 10,000 and enlarged up to mental models no degeneration has been observed in the pri- x30,000. NF and MT were counted in the entire cross-sec- mary optic pathway despite the presence of numerous en- tion of axons with areas ranging from 0.15 to 0.75 ,Um2; 171 larged axons (6-8). axons from control and 226 from experimental animals were used. Student's t test and two-way analysis of variance were Methyl n-butyl ketone, n-hexane, and their metabolite 2,5- used hexanedione (2,5-HxD) (9, 10) are toxic agents that cause for the statistical analysis of axonal area and number of distal giant axonopathies. Methyl n-butyl ketone and n-hex- MT and NF per axon, respectively. Abbreviations: SCb, slow component b; SCa, slow component a; The publication costs of this article were defrayed in part by page charge NF, neurofilaments; MT, microtubules; IF, intermediate filaments; payment. This article must therefore be hereby marked "advertisement" 2,5-HxD, 2,5-hexanedione. in accordance with 18 U.S.C. §1734 solely to indicate this fact. *To whom reprint requests should be addressed. 920 Downloaded by guest on September 23, 2021 Neurobiology: Monaco et aL Proc. NatL Acad. Sci. USA 82 (1985) 921 Axonal Transport. Fifteen experimental and nine control polypeptides were identified as the NF subunits by their lo- rats were injected intraocularly with 500 gCi (1 Ci = 37 GBq) cations in fluorograms of two-dimensional gel electrophore- of L-[35S]methionine (New England Nuclear) from the 4th to sis (Fig. 2). As assessed from quantitation of radioactivity in the 9th week of treatment and sacrificed 25 or 50 days after the Mr 145,000 NF subunit, the distribution of labeled NF in labeling. In three experimental and three control rats, 2,5-HxD-treated animals (Fig. 3A) was significantly different [35S]methionine was injected 10 days before administration from that of the controls and appeared to be bimodal, sug- of 1% 2,5-HxD in drinking water and sacrificed 25 days after gesting that a fraction of the transported NF moved coher- labeling. Optic nerves and tracts were cut in consecutive 3- ently with SCa, as in controls, while another fraction moved mm segments; the chiasm and superior colliculus were used at a rate approaching that of SCb. No significant difference uncut. Each segment was dissolved in 2% NaDodSO4 in 50 was found in the distributions of radioactivity associated mM Tris, pH 6.8; total radioactivity was determined in an with a Mr 30,000 polypeptide representative of SCb (Fig. aliquot of each sample and the remainder was used for one- 3B). and two-dimensional gel electrophoresis, as previously de- Fifty days after labeling, NF polypeptides were present scribed (19); all slab gels were 10% acrylamide, and 6% Am- only at the level of the last segment of the optic tract and of pholines (LKB) was used in the isoelectric focusing gels. the superior colliculus in experimental animals. In controls Fluorography was carried out as described by Bonner and these polypeptides peaked at the 5th segment, 15 mm from Laskey (20). the eyeball. At both 25 and 50 days after labeling, NF poly- Quantitation of Transported Polypeptides. Radioactivity peptides were more prominent in the most distal optic tract associated with a given polypeptide was assessed either by segment than in the superior colliculus, suggesting that at the determining the amount of radioactivity present in the corre- stages of intoxication we studied impairment of transport sponding gel band or by scanning the fluorogram. Labeled and accumulation of NF occurred predominantly in this re- polypeptides in the gel were located by superimposing the gion of the visual system. corresponding fluorogram; bands were excised, incubated Fluorograms from animals whose intoxication began 10 overnight in NCS solubilizer (Amersham)/0.1 M acetic acid days after intraocular labeling, when radioactive slow trans- (9:1, vol/vol) at 60'C and radioactivity was measured by liq- ported proteins had already migrated into the axons, also uid scintillation counting. The areas of the peaks in the fluor- showed a faster moving fraction of NF; these results indicate ogram scans were integrated with a computer-assisted digi- that 2,5-HxD acts on NF already undergoing transport. tizer, using bands corresponding to the Mr 145,000 NF sub- Characterization of the Mr 64,000 and 62,000 Polypeptides.
Recommended publications
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • Inherited Neuropathies
    407 Inherited Neuropathies Vera Fridman, MD1 M. M. Reilly, MD, FRCP, FRCPI2 1 Department of Neurology, Neuromuscular Diagnostic Center, Address for correspondence Vera Fridman, MD, Neuromuscular Massachusetts General Hospital, Boston, Massachusetts Diagnostic Center, Massachusetts General Hospital, Boston, 2 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology Massachusetts, 165 Cambridge St. Boston, MA 02114 and The National Hospital for Neurology and Neurosurgery, Queen (e-mail: [email protected]). Square, London, United Kingdom Semin Neurol 2015;35:407–423. Abstract Hereditary neuropathies (HNs) are among the most common inherited neurologic Keywords disorders and are diverse both clinically and genetically. Recent genetic advances have ► hereditary contributed to a rapid expansion of identifiable causes of HN and have broadened the neuropathy phenotypic spectrum associated with many of the causative mutations. The underlying ► Charcot-Marie-Tooth molecular pathways of disease have also been better delineated, leading to the promise disease for potential treatments. This chapter reviews the clinical and biological aspects of the ► hereditary sensory common causes of HN and addresses the challenges of approaching the diagnostic and motor workup of these conditions in a rapidly evolving genetic landscape. neuropathy ► hereditary sensory and autonomic neuropathy Hereditary neuropathies (HN) are among the most common Select forms of HN also involve cranial nerves and respiratory inherited neurologic diseases, with a prevalence of 1 in 2,500 function. Nevertheless, in the majority of patients with HN individuals.1,2 They encompass a clinically heterogeneous set there is no shortening of life expectancy. of disorders and vary greatly in severity, spanning a spectrum Historically, hereditary neuropathies have been classified from mildly symptomatic forms to those resulting in severe based on the primary site of nerve pathology (myelin vs.
    [Show full text]
  • Peripheral Neuropathy in Complex Inherited Diseases: an Approach To
    PERIPHERAL NEUROPATHY IN COMPLEX INHERITED DISEASES: AN APPROACH TO DIAGNOSIS Rossor AM1*, Carr AS1*, Devine H1, Chandrashekar H2, Pelayo-Negro AL1, Pareyson D3, Shy ME4, Scherer SS5, Reilly MM1. 1. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 2. Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 3. Unit of Neurological Rare Diseases of Adulthood, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy. 4. Department of Neurology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA 5. Department of Neurology, University of Pennsylvania, Philadelphia, PA 19014, USA. * These authors contributed equally to this work Corresponding author: Mary M Reilly Address: MRC Centre for Neuromuscular Diseases, 8-11 Queen Square, London, WC1N 3BG, UK. Email: [email protected] Telephone: 0044 (0) 203 456 7890 Word count: 4825 ABSTRACT Peripheral neuropathy is a common finding in patients with complex inherited neurological diseases and may be subclinical or a major component of the phenotype. This review aims to provide a clinical approach to the diagnosis of this complex group of patients by addressing key questions including the predominant neurological syndrome associated with the neuropathy e.g. spasticity, the type of neuropathy, and the other neurological and non- neurological features of the syndrome. Priority is given to the diagnosis of treatable conditions. Using this approach, we associated neuropathy with one of three major syndromic categories - 1) ataxia, 2) spasticity, and 3) global neurodevelopmental impairment. Syndromes that do not fall easily into one of these three categories can be grouped according to the predominant system involved in addition to the neuropathy e.g.
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Pili Torti: a Feature of Numerous Congenital and Acquired Conditions
    Journal of Clinical Medicine Review Pili Torti: A Feature of Numerous Congenital and Acquired Conditions Aleksandra Hoffmann 1 , Anna Wa´skiel-Burnat 1,*, Jakub Z˙ ółkiewicz 1 , Leszek Blicharz 1, Adriana Rakowska 1, Mohamad Goldust 2 , Małgorzata Olszewska 1 and Lidia Rudnicka 1 1 Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland; [email protected] (A.H.); [email protected] (J.Z.);˙ [email protected] (L.B.); [email protected] (A.R.); [email protected] (M.O.); [email protected] (L.R.) 2 Department of Dermatology, University Medical Center of the Johannes Gutenberg University, 55122 Mainz, Germany; [email protected] * Correspondence: [email protected]; Tel.: +48-22-5021-324; Fax: +48-22-824-2200 Abstract: Pili torti is a rare condition characterized by the presence of the hair shaft, which is flattened at irregular intervals and twisted 180◦ along its long axis. It is a form of hair shaft disorder with increased fragility. The condition is classified into inherited and acquired. Inherited forms may be either isolated or associated with numerous genetic diseases or syndromes (e.g., Menkes disease, Björnstad syndrome, Netherton syndrome, and Bazex-Dupré-Christol syndrome). Moreover, pili torti may be a feature of various ectodermal dysplasias (such as Rapp-Hodgkin syndrome and Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome). Acquired pili torti was described in numerous forms of alopecia (e.g., lichen planopilaris, discoid lupus erythematosus, dissecting Citation: Hoffmann, A.; cellulitis, folliculitis decalvans, alopecia areata) as well as neoplastic and systemic diseases (such Wa´skiel-Burnat,A.; Zółkiewicz,˙ J.; as cutaneous T-cell lymphoma, scalp metastasis of breast cancer, anorexia nervosa, malnutrition, Blicharz, L.; Rakowska, A.; Goldust, M.; Olszewska, M.; Rudnicka, L.
    [Show full text]
  • Jan-March 2015
    NEUROLOGICAL RARE DISEASE 1-855-HELPCMT SPECIAL REPORT www.hnf-cure.org FEBRUARY 2015 TM SELECTED ARTICLES 6 I Rare Diseases Are Not So Rare in Neurology update 14 I Assessing the Burden CMT Winter 2015 of Illness in Narcolepsy 22 I Bright Spotty Lesions May Indicate Neuromyelitis Optica Spectrum Disorder 30 I Multiple System Atrophy Versus Parkinson’s Disease: Similarities and Differences The Hereditary Neuropathy48 I New Tool May Help Breaking News: First Therapeutic Gene Identify Cognitive Deficits in Huntington’s Disease A SUPPLEMENTFoundation’s TO NEUROLOGY REVIEWS mission is to increase Therapy to Treat an Inherited Neuropathy awareness and accurate diagnosis of Charcot-Marie-Tooth (CMT) is Approved for Clinical Trial! and related inherited neuropathies, support patients and families with The first disease community to receive a therapeutic gene to the spinal cord for critical information to improve an ultra rare inherited neuropathy is Giant Axonal Neuropathy (GAN). Congratulations quality of life, and fund research to Hannah’s Hope Fund (HHF), a 501(c)3 public charity, which has driven this that will lead to treatments and collaborative research in less than six years. Six million dollars has been raised to cures. date to fund pre-clinical and clinical research on this rare disease. The Phase 1 trial is recruiting - info here: Intrathecal Administration of scAAV9/ JeT-GAN for the Treatment of Giant Axonal Neuropathy patients. A benign viral Inside This Issue vector known as adeno associated virus serotype 9 (AAV9) is the “Fed-Ex truck” delivering a healthy copy of the GAN gene to the nerves in the spinal cord of affected patients.
    [Show full text]
  • Intermediate Filament Protein Accumulation in Motor Neurons Derived from Giant Axonal Neuropathy Ipscs Rescued by Restoration Of
    Human Molecular Genetics, 2015, Vol. 24, No. 5 1420–1431 doi: 10.1093/hmg/ddu556 Advance Access Publication Date: 4 November 2014 Original Article ORIGINAL ARTICLE Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin Bethany L. Johnson-Kerner1,2,3,4,†, Faizzan S. Ahmad10,‡,¶, Alejandro Garcia Diaz1, John Palmer Greene1, Steven J. Gray7, Richard Jude Samulski7, Wendy K. Chung6, Rudy Van Coster8, Paul Maertens9, Scott A. Noggle10, Christopher E. Henderson1,2,3,4,5, and Hynek Wichterle1,2,3,4,* 1Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, New York, NY 10032, USA, 2Center for Motor Neuron Biology and Disease, 3Departments of Pathology and Cell Biology, Neurology, and Neuroscience, 4Columbia Stem Cell Initiative, 5Department of Rehabilitation and Regenerative Medicine, 6Department of Pediatrics and Medicine, Columbia University Medical Center, New York, NY 10032, USA, 7Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 8Department of Pediatrics, Division of Pediatric Neurology and Metabolism, Ghent University Hospital, Ghent, Belgium, 9Departments of Pediatric Neurology, University of South Alabama, Mobile, AL, USA, and 10New York Stem Cell Foundation, New York, NY 10032, USA *To whom correspondence should be addressed. Tel: +1 2123423929; Fax: +1 2123421555; Email: [email protected] Abstract Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells.
    [Show full text]
  • Genetic Neuromuscular Disease *
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.73.suppl_2.ii12 on 1 December 2002. Downloaded from GENETIC NEUROMUSCULAR DISEASE Mary M Reilly, Michael G Hanna ii12* J Neurol Neurosurg Psychiatry 2002;73(Suppl II):ii12–ii21 he clinical practice of neuromuscular disease is currently undergoing enormous change as a direct result of the wealth of recent molecular genetic discoveries. Indeed, the majority of gene Tdiscoveries in the area of neurological disease relate to neuromuscular disorders. The immedi- ate impact of these discoveries is that a precise DNA based diagnosis is possible. This often gives patients accurate prognostic and genetic counselling information. It will also facilitate rational screening programmes for recognised complications such as cardiac or respiratory involvement. Unfortunately, at present many eligible patients do not benefit from or have access to such diagnostic precision, although this is changing. The discovery of new genes and proteins has opened up unexplored avenues of research into therapies for neuromuscular patients. While therapeutic trials in genetic neuromuscular diseases remain in their infancy, it seems clear that a precise DNA based diagnosis will be essential. Eligi- bility for such trials and indeed for future proven therapies will be contingent upon DNA based diagnosis. For example, it is no longer acceptable to make “limb-girdle muscular dystrophy” based on simple histochemistry, a final diagnosis. Detailed immunocytochemistry and protein chemistry in combination with DNA analysis offer the patient the best chance of a precise diagnosis from which accurate prognostication, screening, and genetic counselling will follow. In this review we describe some of the more common genetic nerve and muscle diseases encountered by adult neurologists.
    [Show full text]
  • Charcot-Marie-Tooth Disease and Related Hereditary Neuropathies
    Charcot-Marie-Tooth Disease and Related Hereditary Neuropathies Charcot-Marie-Tooth (CMT) disease is a hereditary neuropathy with many types and subtypes, including types 1 (CMT1), 1A (CMT1A), 2 (CMT2), and 4 (CMT4), among others. Disorders with similar clinical findings include hereditary motor neuropathy Tests to Consider (HMN), hereditary motor and sensory neuropathy (HMSN), hereditary sensory neuropathies (HSN), hereditary sensory and autonomic neuropathies (HSAN), and Charcot-Marie-Tooth (CMT) and Related hereditary neuropathy with liability to pressure palsies (HNPP). Diagnostic testing for Hereditary Neuropathies, PMP22 Deletion/Duplication with Reflex to these conditions can be performed to confirm the diagnosis in symptomatic Sequencing Panel 2012155 individuals or to identify family members at risk for developing the condition; genetic Method: Multiplex Ligation-dependent Probe etiology generally determines the CMT type and subtype. Amplification/Massively Parallel Sequencing Recommended test for suspected autosomal dominant or sporadic Disease Overview demyelinating CMT, CMT1 or CMT1A. Deletion/duplication of PMP22 gene is Prevalence of CMT hereditary neuropathy – 1/3,300 performed first. If no large deletions or duplications are detected and/or results do Age of onset – first through third decade not explain the clinical scenario, sequencing of hereditary neuropathy genes is performed (see Genes Tested table for Diagnosis of Hereditary Neuropathy gene list). Deletion/duplication and sequencing Based on combination of: components
    [Show full text]
  • RARE Foundation Alliance List RARE Hub 2021-08
    The Global Genes RARE Foundation Alliance is made up of over 750 disease foundations that have committed to collaborating with Global Genes and other nonprofit foundations in order to create a stronger, collective voice in the rare disease community. #Bold Lips For Sickle Cell – Sickle Cell Disease 11q Research & Resource Group – Jacobsen Syndrome, 11q Chromosome 1p36 Deletion Support & Awareness – 1p36 Deletion Syndrome 22q 11 Ireland support group – 22q11.2 deletion syndrome 4p- Support Group – Wolf-Hirschhorn Syndrome and related 4p conditions 5p-Society– 5p- Syndrome, Cat Cry Syndrome, Cri du Chat Syndrome 17q12 Foundation - 17q12 Deletions and Duplications A Breath Of Hope Foundation For NMO - Neuromyelitis Optica A Foundation Building Strength for Nemaline Myopathy – Nemaline Myopathy A Nonprofit Group Enriching Lives (ANGEL AID) - Multiple rare diseases Aaron’s Ohtahara – Ohtahara Syndrome Acid Maltase Deficiency Association– Acid Maltase Deficiency, Pompe’s Disease Acromegaly Community – Acromegaly and Gigantism Acromegaly Ottawa Awareness & Support Network - Acromegaly Acoustic Neuroma Association – Acoustic Neuroma ADCY5.org – ADCY5 Mutation Addi & Cassi Fund – Niemann Pick Type C ADNPkids – ADNP Syndrome, Helsmoortal_Van Der AA Syndrome Adrenal Alternatives Foundation - Adrenal Diseases Adrenal Insufficiency United – Adrenal Insufficiency Adult Polyglucosan Body Disease Research Foundation (APBDRF) – APBD Advancing Sickle Cell Advocacy Project, Inc. – Sickle Cell Disease Advocacy & Awareness for Immune Disorders Association – Primary
    [Show full text]
  • Download CGT Exome V2.0
    CGT Exome version 2.
    [Show full text]
  • Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms
    PROTEOSTASIS OF GLIAL INTERMEDIATE FILAMENTS: DISEASE MODELS, TOOLS, AND MECHANISMS Rachel Anne Battaglia A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Cell Biology and Physiology in the School of Medicine. Chapel Hill 2021 Approved by: Natasha T. Snider Carol Otey Keith Burridge Douglas Cyr Mohanish Deshmukh Damaris Lorenzo i © 2021 Rachel Anne Battaglia ALL RIGHTS RESERVED ii ABSTRACT Rachel Anne Battaglia: Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms (Under the direction of Natasha T. Snider) Astrocytes are a major glial cell type that is crucial for the health and maintenance of the Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) are components of the astrocyte cytoskeleton that support many of these functions in healthy individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to accumulation and aggregation. These processes are thought to contribute to disease pathogenesis of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of pharmacological tools to modulate their assembly and disassembly states. Moreover, the mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post- translational modifications (PTMs) in this process.
    [Show full text]